{"organizations": [], "uuid": "e241ed6537e385bbc499c1ce77e7717d068679ff", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/31/globe-newswire-biogen-appoints-daniel-karp-as-evp-corporate-development.html", "country": "US", "domain_rank": 767, "title": "Biogen Appoints Daniel Karp as EVP, Corporate Development", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-31T15:30:00.000+03:00", "replies_count": 0, "uuid": "e241ed6537e385bbc499c1ce77e7717d068679ff"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/31/globe-newswire-biogen-appoints-daniel-karp-as-evp-corporate-development.html", "ord_in_thread": 0, "title": "Biogen Appoints Daniel Karp as EVP, Corporate Development", "locations": [], "entities": {"persons": [{"name": "daniel karp", "sentiment": "positive"}, {"name": "michel vounatsos", "sentiment": "none"}, {"name": "karp", "sentiment": "none"}, {"name": "vounatsos", "sentiment": "none"}, {"name": "daniel", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}], "organizations": [{"name": "biogen", "sentiment": "positive"}, {"name": "pfizer", "sentiment": "none"}, {"name": "executive committee", "sentiment": "none"}, {"name": "worldwide business development", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Seasoned executive brings strong track record of success leading licensing and M&A transactions\nCAMBRIDGE, Mass., Biogen (Nasdaq:BIIB) announced today the appointment of Daniel Karp as Executive Vice President, Corporate Development effective June 11, 2018.\nKarp will lead the newly created Corporate Development function, which will include corporate and business development and corporate strategy. He will be a member of the Executive Committee and report directly to Michel Vounatsos, Biogen’s Chief Executive Officer.\n“We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience,” Vounatsos said. “Daniel’s solid experience from Pfizer combined with his scientific and business education will serve him well in this exciting position as we aim to further build our pipeline and portfolio to tackle unmet needs in neurological diseases.”\nDaniel joins Biogen from Pfizer where he most recently was Vice President, Worldwide Business Development and head of business development for R&D. In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer’s research portfolio. In over a decade at Pfizer, he held corporate and business development roles spanning rare diseases, gene therapy, vaccines, oncology and specialty care, with experience including mergers and acquisitions, licensing and scientific collaborations. In recent years, he has been involved in several high-profile acquisitions and led business development organizations that executed hundreds of agreements, licenses and collaborations. His experience also includes healthcare and life sciences strategy consulting.\n“It’s a privilege to join Biogen, a true leader in neuroscience,” Karp said. “I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.\"\nKarp holds a BS in Biology from Duke University and an MBA from the Wharton School of Business at the University of Pennsylvania.\nAbout Biogen\nAt Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.\nWe routinely post information that may be important to investors on our website at www.biogen.com . To learn more, please visit www.biogen.com and follow us on social media – Twitter , LinkedIn , Facebook , YouTube .\nBiogen Safe Harbor\nThis press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities, our strategy and plans, the potential of our commercial business and pipeline programs and the expected benefits from Karp’s appointment as our Executive Vice President, Corporate Development. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements.\nThese statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; potential future healthcare reforms; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.\nContact:\nBiogen\nMEDIA:\nDavid Caouette, +1 617-679-4945\npublic.affairs@biogen.com\nor\nINVESTORS:\nMike Henke, +1 781-464-2442\nIR@biogen.com\nSource:Biogen Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=To2EPQ65YJP59Cu1LgmReEVCsKRl5eIU9ptP6sPSgOz5mJAUfbsf29z4XkT0ZeUZ3lLKdOV7wCKTLS6PI4gMRQ==", "https://www.globenewswire.com/Tracker?data=To2EPQ65YJP59Cu1LgmReJW7B8R-_SEx8c0Cy25lncIM8Sls-ugu7wH3pQtmSUcAtPBXJ5ELY0CiKoDzx_8v1A==", "https://www.globenewswire.com/Tracker?data=sPLJorCTvVlHSkidlpOeLegyhzihp-ycqSb_Mjmnd99BjtSKhHZk5DYhyLq10Rn_zlYXG15NwL0LmOA3WOqNDg==", "https://www.globenewswire.com/Tracker?data=i4IeuD9oHVPP2BueyEdFnZf3Y-I-s90F-HzSdB0L_p5Kq6_iR3QjG3xOSG-XnIJ3qwU68eBbKEBRTP8tXb1Bg0q9nRK9x23jXPiDho2_fhM=", "https://www.globenewswire.com/Tracker?data=FBEJAMO72Zbu_-hczEeVGfUhdKuPZHhKWUvtIgFRElEHQ7j9hzXMdOytl9Uh2Rpg3qbrRzcykSQSGP_X-_YvYk5IFohXiTF5Hu0Bw_dx9wo=", "https://www.globenewswire.com/Tracker?data=JvfUCffW_-R3OpO244X9VIW4-7q-mSWqPDgeJFgki7unHjfBiJqyOfeLgF0ycp2PWC-3B5pz_xNM86UU_GsRSg==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/80f9c524-3da2-4583-a763-0dad931fa182", "https://www.globenewswire.com/Tracker?data=_cEB75HlQh7MjDx8oC5HbaAJSPUcotgkWbIOOHIA5jVqviMzldkU6sKmjQCPMp6AgFmuAeoLAG_XeYDnZPvXjw==", "https://www.globenewswire.com/Tracker?data=WL9vNKp_yI23LKP9ls6RWWqT9IIGB4znKwdhKO5vcWMYU3-0fQXH-DnxnRKZahew2--T0QEU_PImau2La79lbQ==", "https://www.globenewswire.com/Tracker?data=nltFNRZnN2berJEs0wqIjj8m5EaHAbQZ_meBSfQvrLrVD9--JLuLH3XV74tuyQo0mqLM0s84nncFbKEWqdlcNA=="], "published": "2018-05-31T15:30:00.000+03:00", "crawled": "2018-05-31T16:40:31.010+03:00", "highlightTitle": ""}